Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline

🤖 Plain-English Summary

Abstract Background This American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Asociación Latinoamericana de Tórax guideline updates prior idiopathic pulmonary fibrosis (IPF) guidelines and addresses the progression of pulmonary fibrosis in patients with interstitial lung diseases (ILDs) other than IPF. A conditional recommendation was made for nintedanib, and additional research into pirfenidone was recommended.

🔑 Key Findings

• Methods A committee was composed of multidisciplinary experts in ILD, methodologists, and patient representatives.
• 1) Update of IPF: Radiological and histopathological criteria for IPF were updated by consensus.
• Questions about transbronchial lung cryobiopsy, genomic classifier testing, antacid medication, and antireflux surgery were informed by systematic reviews and answered with evidence-based recommendations using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach.

🔗 Related Resources